Literature DB >> 10839332

Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report.

S J Watson1, J A Benson, J E Joy.   

Abstract

In response to public pressure to allow the medical use of marijuana, the Office of National Drug Control Policy, Washington, DC, funded a study by the Institute of Medicine evaluating the scientific evidence for benefits and risks of using marijuana as a medicine. The report used scientific reviews, public hearings, and reports from other agencies, and was evaluated by knowledgeable advisors and reviewers. It called for heavier investment in research on the biology of cannabinoid systems, careful clinical studies of cannabinoids in clinical syndromes, analysis of cannabinoids' psychological effects on symptoms, and evaluations of the health consequences of heavy marijuana use; recommends against the use of smoked marijuana in medicine and for the development of a medical cannabinoid inhaler; and recommends that compassionate use of marijuana be considered under carefully reviewed protocols. Finally, the report evaluates the abuse potential, tolerance, withdrawal, and gateway risks of medical use of cannabinoid drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10839332     DOI: 10.1001/archpsyc.57.6.547

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  58 in total

1.  [Epidemiological study of risk behaviour in adolescents at school in two populations, semi-rural and urban].

Authors:  J González Lama; J R Calvo Fernández; P Prats León
Journal:  Aten Primaria       Date:  2002-09-15       Impact factor: 1.137

Review 2.  Blurred boundaries: the therapeutics and politics of medical marijuana.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 3.  Cannabinoid neuroimmune modulation of SIV disease.

Authors:  Patricia E Molina; Angela Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter Winsauer; Curtis Vande Stouwe
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-10       Impact factor: 4.147

4.  Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.

Authors:  Erin L Karschner; W David Darwin; Robert S Goodwin; Stephen Wright; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-11-15       Impact factor: 8.327

Review 5.  Cannabinoid receptors and endocannabinoids: evidence for new players.

Authors:  Ken Mackie; Nephi Stella
Journal:  AAPS J       Date:  2006-04-28       Impact factor: 4.009

6.  CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents.

Authors:  Catherine Lombard; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Clin Immunol       Date:  2006-12-20       Impact factor: 3.969

7.  Subjective and physiological effects after controlled Sativex and oral THC administration.

Authors:  E L Karschner; W D Darwin; R P McMahon; F Liu; S Wright; R S Goodwin; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

8.  Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Authors:  Dayong Lee; Erin L Karschner; Garry Milman; Allan J Barnes; Robert S Goodwin; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2012-11-10       Impact factor: 4.492

9.  Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice.

Authors:  A Zimmer; E Valjent; M Konig; A M Zimmer; P Robledo; H Hahn; O Valverde; R Maldonado
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

10.  Olfactory Hallucinations without Clinical Motor Activity: A Comparison of Unirhinal with Birhinal Phantosmia.

Authors:  Robert I Henkin; Samuel J Potolicchio; Lucien M Levy
Journal:  Brain Sci       Date:  2013-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.